Neoadjuvant chemotherapy Folfirinox, 4 cycles — Competitive Intelligence Brief

Neoadjuvant chemotherapy Folfirinox, 4 cycles (Neoadjuvant chemotherapy Folfirinox, 4 cycles) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Combination chemotherapy regimen. Area: Oncology.

phase 3 Combination chemotherapy regimen Multiple: thymidylate synthase, topoisomerase I, DNA (cross-linking) Oncology Small molecule

Target snapshot

Neoadjuvant chemotherapy Folfirinox, 4 cycles (Neoadjuvant chemotherapy Folfirinox, 4 cycles) — University Hospital, Bordeaux. FOLFIRINOX is a combination chemotherapy regimen that simultaneously attacks cancer cells through multiple mechanisms: fluorouracil and leucovorin inhibit thymidylate synthase to disrupt DNA synthesis, while irinotecan inhibits topoisomerase I to prevent DNA unwinding.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Neoadjuvant chemotherapy Folfirinox, 4 cycles TARGET	Neoadjuvant chemotherapy Folfirinox, 4 cycles	University Hospital, Bordeaux	phase 3	Combination chemotherapy regimen	Multiple: thymidylate synthase, topoisomerase I, DNA (cross-linking)
chemotherapy of mFOLFOX6 or FOLFIRI	chemotherapy of mFOLFOX6 or FOLFIRI	Xu jianmin	marketed	Combination chemotherapy regimen	Thymidylate synthase (5-FU), DNA topoisomerase I (irinotecan), DNA (oxaliplatin)
PTH followed by dose dense AC of FEC	PTH followed by dose dense AC of FEC	Agendia	marketed	Combination chemotherapy regimen with monoclonal antibody	HER2 receptor; microtubule; DNA (topoisomerase II)
SOX Chemotherapy	SOX Chemotherapy	The First Affiliated Hospital with Nanjing Medical University	marketed	Combination chemotherapy regimen
CEV chemotherapy	CEV chemotherapy	Sun Yat-sen University	marketed	Combination chemotherapy regimen
Dexamethasona, Idarubicine, ARA-C, Methotrexate	Dexamethasona, Idarubicine, ARA-C, Methotrexate	PETHEMA Foundation	marketed	Combination chemotherapy regimen
Carboplatin, Etoposide, Ifosfamide	Carboplatin, Etoposide, Ifosfamide	University Hospital Muenster	marketed	Combination chemotherapy regimen	DNA (multiple mechanisms: alkylation, cross-linking, topoisomerase II inhibition)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Combination chemotherapy regimen class)

1. Sun Yat-sen University · 5 drugs in this class
2. Sixth Affiliated Hospital, Sun Yat-sen University · 2 drugs in this class
3. Hoffmann-La Roche · 2 drugs in this class
4. University Hospital, Bordeaux · 2 drugs in this class
5. Beijing Friendship Hospital · 1 drug in this class
6. Centre Hospitalier Universitaire Dijon · 1 drug in this class
7. Amgen · 1 drug in this class
8. Chungnam National University Hospital · 1 drug in this class
9. AstraZeneca · 1 drug in this class
10. Children's Cancer Group, China · 1 drug in this class